Elixir Pharmaceuticals, of Cambridge, Mass., said it has raised $46 million in a third round of funding. The financing includes $31 million in equity funding and $15 million in venture debt placement from Hercules.
The company is developing treatments for a number of diseases, mostly age-related. Here is a brief description of its technology.
The funding came from MPM Capital, Oxford BioScience Partners, ARCH Venture Partners, CDIB Ventures, JAFCO and YFY Biotech Management Company, among others.